Provided are an extract, which is a fractionated component 1 of a water extract of a plant powder, wherein the fractionated component 1 is a fractionated component having a fractionation molecular weight of 12,000 or greater, wherein an ethanol-undissolved component of the fractionated component 1 exhibits a peak attributable to carboxylic acid in a Fourier transform infrared spectroscopy (FT-IR) measurement and exhibits a peak attributable to cellulose in a gas chromatography mass spectrometry (GC-MS) measurement, and wherein an ethanol-dissolved component of the fractionated component 1 exhibits a peak attributable to carboxylic acid in the FT-IR measurement and exhibits a peak attributable to a plant protein in the GC-MS measurement, and a water-purifying agent containing the extract.

This disclosure relates to nanoparticles comprising a surface molecule that binds or blocks PD-L1. In certain embodiments, the disclosure relates to methods of using peptides or nanoparticles disclosed herein for the treatment of cancer. In certain embodiments, the disclosure relates to methods of using nanoparticles disclosed herein for therapeutic and diagnostic applications.

Provided herein are biocompatible polymers having a polymer backbone and one or more repeating units, and methods of making and using the same. The repeating units can each be individually selected from a zwitterionic precursor repeating unit of Formula (1). Also provided are systems for nucleic acid delivery including the biocompatible polymers, the systems having a cationic core and a polysaccharide-anionic peptide conjugate adsorbed to the cationic core.

The present invention is related to the field of intracellular delivery of membrane-impermeable materials. It provides compositions enabling the delivery of such membrane-impermeable materials into cells, applicable for both in vitro, in vivo and ex vivo delivery applications, as well as the use thereof in methods of cytosolic delivery of membrane-impermeable materials. The compositions and methods are particularly useful in biological research, diagnostic methods and the development of cell-based therapies.

The presently disclosed subject matter relates to immunoswitch particles that switch off immunosuppressive pathways on tumor cells or immunosuppressive molecules induced by tumor cells in the tumor microenvironment, or virus infected cells or immunosuppressive molecules induced by virus infected cells in the microenvironment surrounding the virus infected cells, while simultaneously switching on co-stimulatory or co-inhibitory pathways on T cells, as well as method for converting immunosuppressive signals in cells, tissues, and subjects into stimulatory signals, and immunotherapy-based methods for treating cancer and chronic viral infections.

The present invention concerns a polymeric material for the production of a non-viral nanoparticle. The polymeric material comprises (i) a hydrophilic linear polymer having a first end and a second end, (iii) a cross-linkable cationic polymer covalently bonded to the first end of the hydrophilic linear polymer, and (iii) at least one targeting/penetrating peptide covalently associated to the second end of the hydrophilic linear polymer. Also disclosed herein are nanoparticles produced with these polymeric material, processes for making the polymeric material and the nanoparticles as well as use of the nanoparticles.

The present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease and a metabolic disease, which includes hyaluronic acid nanoparticles, and more particularly, to a pharmaceutical composition for preventing or treating an inflammatory disease and a metabolic disease, which includes hyaluronic acid nanoparticles formed in such a way that 5-cholanic acid or polycaprolactone binds to a hydrophobic moiety of hyaluronic acid through self-assembly in an aqueous solution state. The pharmaceutical composition for preventing or treating an inflammatory disease or a metabolic disease, which includes hyaluronic acid nanoparticles, according to the present invention reduces body weight, lowers food intake, has an effect of reducing blood glucose as a result of a glucose tolerance test (GTT), and has an effect of reducing insulin resistance, inflammatory inducers (NF-B, IL-1, CD44, TNF-, NLRP3 inflammasome, and the like), and macrophage tissue infiltration, and thus may be effectively used as a pharmaceutical composition for preventing or treating inflammatory diseases or metabolic diseases.

The present invention provides a composition of nanoparticles comprising a biological mimetic base component that forms the structure of the nanoparticle. By interacting with the functional groups of the base component, the half-life of a bioactive molecule is extended.

Hydrogel nanoparticles and microparticles are prepared by a water-in-oil method from natural polymers that are water miscible, a hydrophobic polyol and a crosslinking agent. The hydrogel nanoparticles are auto fluorescent and can be used for imaging of cells and a biological entity. The hydrogel nanoparticles and microparticles can include magnetic nanoparticles and carry desired bioactive entities. The hydrogel nanoparticles and microparticles are useful for diagnostics and as therapeutics purposes including drug delivery, imaging of drug migration, and selectivity by the tagging or binding of the hydrogel nanoparticles and microparticles with appropriate antibodies or antigens.

The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.